Biocon's executive chairperson says lifestyle changes should remain the first choice, while Zerodha's founder says generic GLP-1 uptake has lagged despite lower prices.
Biocon's executive chairperson Kiran Mazumdar-Shaw has voiced concerns about the long-term risks of GLP-1 drugs, stressing the importance of lifestyle changes. Concurrently, Zerodha's founder Nithin Kamath highlighted the surprisingly weak uptake of generic GLP-1 medicines…
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.